As the only central enterprise directly managed by the State-owned Assets Supervision and Administration Commission of the State Council specializing in life and health, China National Pharmaceutical Group Corporation (hereinafter referred to as “Sinopharm”) is a national innovative enterprise, a central pharmaceutical reserve unit, and a leading comprehensive pharmaceutical and health industry group in China and Asia in terms of comprehensive strength and scale, with a comprehensive health industry chain integrating technical R & D, industrial manufacturing, logistics and distribution, retail chain, medical and health care, engineering technology, professional exhibition, international operation and financial investment etc.<\/p>\r\n","url":"http:\/\/www.sinopharm.com\/56.html","create_time":"2022-01-24 15:18:44"},{"id":34,"name":"Henlius","logo":"https:\/\/www.panacro.com\/upload\/10142f9c14b96e6f\/b9b2b25abf13b7bc.png","introduce":"
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 4 products have been launched in China, 1 in the European Union (EU), 3 New Drug Applications (NDAs) accepted for review in China.<\/p>\r\n\r\n
Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation.<\/p>\r\n","url":"https:\/\/www.henlius.com\/","create_time":"2022-03-28 14:15:12"},{"id":35,"name":"Fosun Pharma","logo":"https:\/\/www.panacro.com\/upload\/915dc202e9cf9f5f\/190388d5889ebd8d.png","introduce":"
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading innovation-driven international healthcare group in China. Fosun Pharma strategically operates businesses in the pharmaceutical and health industry, including pharmaceutical manufacturing, medical devices and medical diagnosis, and healthcare services. Through equity participation in Sinopharm Co., Ltd., Fosun Pharma’s business extends to pharmaceutical distribution and retail.<\/p>\r\n\r\n
Fosun Pharma takes pharmaceutical manufacturing as its core business and sticks to innovative research and development. Through in-house R&D, co-development, in-licensing and incubation, Fosun Pharma had established platforms for small molecule innovative drugs, antibody drugs and cell therapy, focusing on major therapeutic areas, including oncology, immunology, “4 hypers” (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia) and their complications, as well as central nervous system. In the meantime, Fosun Pharma keeps close track of cutting-edge technologies, such as targeted protein degradation, RNA, oncolytic virus and gene therapy to enhance its innovation ability.<\/p>\r\n\r\n
Looking forward, under guidance of 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. Fosun Pharma is committed to becoming the first-class enterprise in the global mainstream healthcare industry.<\/p>\r\n","url":"https:\/\/www.fosunpharma.com\/","create_time":"2022-03-28 14:16:17"},{"id":36,"name":"Jemincare","logo":"\/upload\/cafe0f47386a32af\/fedfd8eaadcd45c9.png","introduce":"
Founded in 1999, Jemincare is a leading health industry group in China. Headquartered in Nanchang, China, Jemincare has more than 12,000 employees and its business covers the fields of medicine and health, clean energy, green mineral development and industrial investment. In 2021, its revenue will exceed 41 billion yuan. Adhering to the innovation-driven strategy, Jemincare provides reliable guarantee for human health through endogenous growth, extension expansion and integrated development, and promotes global green and sustainable development. Jemincare is committed to becoming an international advanced modern big health industry group.<\/p>\r\n\r\n
Jemincare has established an integrated international pharmaceutical RESEARCH and development system in Shanghai, Nanjing and New Jersey, USA. By setting up 10 pharmaceutical bases in Jiangxi, Jiangsu, Zhejiang, Jilin and other provinces, Jemincare promotes the global development and transformation of cutting-edge technologies and products such as biological macromolecules, chemical small molecules and innovative Traditional Chinese medicine. Our products have been exported to more than 30 countries and regions in Europe and America, ranking among the top ten of the Top 100 pharmaceutical industry in China for many consecutive years.<\/p>\r\n","url":"http:\/\/www.jemincare.com\/","create_time":"2022-03-28 14:17:23"},{"id":37,"name":"Qyuns Therapeutics","logo":"\/upload\/7507bf88f28402cd\/8efdb53e12c03dad.png","introduce":"
Qyuns Therapeutics was established in 2015, and the founding team consists of overseas returnee doctors and senior experts in the domestic biopharmaceutical industry.<\/p>\r\n\r\n
The company specializes in the R&D of antibody drugs in the field of autoimmunity and allergy, and is committed to developing, manufacturing and selling therapeutic antibody drugs that meet international specifications and specifications.<\/p>\r\n\r\n
Through completely independent R&D, the company has formed a product line of 12 innovative varieties, covering the autoimmunity and allergy-related fields of psoriasis, atopic dermatitis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, asthm, etc.<\/p>\r\n","url":"http:\/\/www.qyuns.net\/","create_time":"2022-03-28 14:18:08"},{"id":38,"name":"Ascletis","logo":"\/upload\/8b06d2bf969f2a16\/197f7a3954f30536.png","introduce":"
Ascletis Pharma Inc. was established in 2013, and was listed on the Hong Kong Stock Exchange in 2018 (1672.HK).<\/p>\r\n\r\n
Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, non-alcoholic steatohepatitis\/primary biliary cholangitis, and tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors) to address clinical needs of patients at home and abroad.<\/p>\r\n\r\n
Gannex, a wholly-owned subsidiary of Ascletis, is fully dedicated to R&D and commercialization of new drugs in the field of NASH.<\/p>\r\n","url":"https:\/\/www.ascletis.com\/","create_time":"2022-03-28 14:18:48"},{"id":39,"name":"MAB Works","logo":"https:\/\/www.panacro.com\/upload\/2c63a42a03cf5b9b\/d196914077dfdcd6.png","introduce":"
MAB Works is a clinical-stage biopharmaceutical company in China, focusing on discovery and development of innovative and differentiated antibody drugs. We strive to become a globally integrated biopharmaceutical company.<\/p>\r\n\r\n
Our mission is to transform the scientific breakthrough of immunology and carcinobiology into novel antibody therapies, covering the biologic drug market of oncology and autoimmune diseases, which is a market growing rapidly globally and in China, with unmet clinical demand.<\/p>\r\n\r\n
We will leverage this opportunity to bring innovative and affordable treatment regimens for patients in such fields continuously.<\/p>\r\n","url":"http:\/\/www.mab-works.com\/","create_time":"2022-03-28 14:19:33"},{"id":40,"name":"Binhui Biopharm","logo":"https:\/\/www.panacro.com\/upload\/f9a4cd98658201dc\/4b95debf088315e6.png","introduce":"
Founded in 2010, Binhui Biopharmaceutical Co., Ltd. is a leading independent company of oncolytic virus immunotherapy in China, devoting to research and development in OV for more than ten years.<\/p>\r\n\r\n
The company created the oncolytic virus (OV) technology platform, its first product has obtained 3 IND approvals for OV mono and combo therapies, and is the only product conducted multiple Phase II clinical trials for mono and combo therapies with OV in various indications in China, which showed promising therapeutic effect.<\/p>\r\n\r\n
In August 2021, BS001(OH2) injection was approved by the U.S. FDA for clinical trial of various indications in the US.<\/p>\r\n","url":"http:\/\/www.binhui-bio.com\/","create_time":"2022-03-28 14:20:14"},{"id":41,"name":"Recbio","logo":"\/upload\/72ef23b4df674469\/9337cbaf9f21be64.png","introduce":"
Jiangsu Recbio Co., Ltd. (Recbio or The Company) is an innovative vaccine company dedicated to the development and commercialization of safer and more effective innovative vaccines to address the public health need that is far from being met.<\/p>\r\n\r\n
Recbio has high-value vaccine portfolio driven by self-developed novel adjuvant technologies and protein engineering technologies.<\/p>\r\n\r\n
Through its strong R&D capabilities, the company has built a robust and innovative vaccine portfolio of 11 vaccine candidates, with coverage strategically expanding to areas covered by 5 of the top 10 most expensive diseases in the Global Burden of Disease assessed by the World Health Organization's DALYs released in 2019, and 3 of the top 5 best-selling vaccine products in the world in 2020.<\/p>\r\n","url":"https:\/\/www.recbio.cn\/","create_time":"2022-03-28 14:20:55"},{"id":42,"name":"CSPC","logo":"https:\/\/www.panacro.com\/upload\/08cdc659e6480da8\/7741bdbce84ec75a.png","introduce":"
CSPC Pharmaceutical Group Co., Ltd. (CSPC) is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs.<\/p>\r\n\r\n
The group’s total assets are 50 billion RMB, with 27000 employees.<\/p>\r\n\r\n
Hong Kong-Listed Company (01093.HK), among 100 billion market value club, is the component stock of HSI.<\/p>\r\n\r\n
In 2019, CSPC Innovation (300765.SZ), a subsidiary of CSPC, successfully listed on the GEM, which realized the “Red Chip + A” financing pattern new era of the CSPC Group.<\/p>\r\n\r\n
At present, there are more than 10 pharmaceutical production bases in Hebei, Shanxi, Shandong, Jiangsu, Jiangxi, Tianjin, and other provinces and cities. The products are sold in more than 100 countries and regions around the world, and 36 single varieties sold over 100 million RMB.<\/p>\r\n","url":"http:\/\/www.e-cspc.com\/","create_time":"2022-03-28 14:21:40"},{"id":43,"name":"Huaota Biopharm","logo":"https:\/\/www.panacro.com\/upload\/a6c9051184860435\/22c7b9ab40cd5f04.png","introduce":"
Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd.<\/p>\r\n\r\n
Driven by innovation and development, Huaota has built comprehensive and integrated platforms to develop novel biologics, including the R&D platform at Huaota supports the identification and development of new monoclonal antibodies, bispecific antibodies, fusion proteins, ADC drugs, etc., and the pilot platform for stock solutions and preparations in compliance with applicable GMP standards.<\/p>\r\n\r\n
Disposable technology and the world's leading 200L and 1000L disposable bioreactors from GE were employed in the DS pilot production. The preparations workshop is equipped with complete sets of vials and prefilled syringe filling lines imported from BOSCH Germany, supporting various ways of administration. The quality control lab has a variety of advanced analytical instruments fulfilling the analytical needs, such as product release and stability studies, of supporting production, registration, and clinical trials.<\/p>\r\n","url":"https:\/\/www.huaota.com\/","create_time":"2022-03-28 14:22:20"},{"id":44,"name":"GPHL","logo":"https:\/\/www.panacro.com\/upload\/1b7c817e36c7d774\/1c21aff048c0f714.png","introduce":"
Guangzhou Pharmaceutical Holdings Limited (GPHL) is a wholly state-owned enterprise authorized by Guangzhou municipal government to operate state-owned assets. GPHL is dedicated to the research and development of Chinese patent medicine, Chinese herbal medicine, chemical pharmaceutical raw materials and preparations, biological medicine and healthcare products, and to pharmaceutical logistics and distribution and healthcare service. As a large enterprise winning the municipal government's key support for development, GPHL integrates the research, manufacturing and trading of medicine.<\/p>\r\n","url":"http:\/\/en.gpc.com.cn\/","create_time":"2022-03-28 14:22:55"},{"id":45,"name":"Guojian Pharmaceutical","logo":"https:\/\/www.panacro.com\/upload\/e154939b3b90b7d6\/c86cb9184d7a37e4.png","introduce":"
Founded in 2002, Guojian Pharmaceutical is one of the first batch of Chinese innovative biopharmaceutical enterprises focusing on antibody drugs and is also a domestic pharmaceutical enterprise with three listed therapeutic antibody drugs in China. It has grown to become a biopharmaceutical company in China with independent capabilities in research and development, manufacturing and commercialization.<\/p>\r\n\r\n
With the National Engineering Research Center of Antibody Medicine, the company operates the production base of antibody drugs with a total scale of more than 40,000 liters.<\/p>\r\n\r\n
The company's R&D mainly focuses on innovative therapeutic antibody drugs, and provides high-quality, safe and effective clinical solutions for the treatment of autoimmune diseases, tumors and other major diseases.<\/p>\r\n\r\n
Adhering to the concept of "Cherish Life, Care for Life, Create Life", Guojian Pharmaceutical is committed to growing an innovative therapeutic antibody drug enterprise that benefits China and embraces the world, realizing the vision of "making innovative antibody drugs within reach", so as to benefit more people and contribute to the Healthy China.<\/p>\r\n","url":"https:\/\/www.3s-guojian.com\/","create_time":"2022-03-28 14:24:21"},{"id":46,"name":"Genrixbio","logo":"https:\/\/www.panacro.com\/upload\/4ce6fb64ec1b6241\/a9ab016d5ccb03e4.png","introduce":"
As an innovation-driven biotechnology company, Genrixbio (Shanghai) Technology Co., Ltd. (hereinafter referred to as Genrixbio) was jointly founded by a number of senior experts in the biopharmaceutical industry and the actual controller of the A-share listed company Genrixbio in Zhangjiang, Shanghai in June 2014. The company is engaged in the development and industrialization of biotechnology drugs such as therapeutic monoclonal antibodies and fusion proteins. We have established several technical platforms covering the whole life cycle of antibody drug development, including discovery and screening of innovative antibody drugs, process development and quality characterization of highly expressed cell lines of antibody drugs, pilot and industrialized process scale-up production, pharmacological and toxicological research, clinical research and registration filing, etc.<\/p>\r\n\r\n
Currently, a number of innovative drugs developed by the company have entered the clinical study stage, with indications including multiple oncology and autoimmune system diseases, and more than a dozen high-potential innovative varieties are in various stages of druggability assessment , pre-clinical study or preparation for IND application.<\/p>\r\n","url":"www.genrixbio.com","create_time":"2022-03-28 14:25:11"},{"id":47,"name":"Immune-path","logo":"https:\/\/www.panacro.com\/upload\/3edca2dee25ae100\/5fa8aaecf1e1f637.png","introduce":"
Founded in 2017, Immune-path Biotechnology (Suzhou) Co., Ltd. is led by national specially-appointed experts, and founded by vaccine R&D professionals at home and abroad and an elite team of pharmaceutical companies.<\/p>\r\n\r\n
The company is a high-tech biopharmaceutical enterprise headquartered in Suzhou High-tech Zone. It is invested by a number of top domestic and foreign funds, including Lilly Asia Ventures, Qiming Venture Capital, Orbimed, Loyal Valley Capital, Northern Light Venture Capital, Bio Venture, Green Pine Capital, and SND Group.<\/p>\r\n","url":"https:\/\/www.immune-path.com\/","create_time":"2022-03-28 14:25:56"},{"id":48,"name":"Huadong Medicine","logo":"https:\/\/www.panacro.com\/upload\/98a0b7544cb9c801\/068b47ca53787b89.png","introduce":"
Huadong Medicine Co., Ltd. (stock code: 000963) was founded in 1993, headquartered in Hangzhou, Zhejiang Province, and listed on the Shenzhen Stock Exchange in December 1999.<\/p>\r\n\r\n
Dominated by the pharmaceutical industry, while expanding the pharmaceutical business and medical beauty industry, the company's business covers the entire pharmaceutical industry chain, and has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical research and development, production and distribution.<\/p>\r\n\r\n
The company has always adhered to the corporate philosophy of “scientific research-based and patient-centered” and is committed to becoming a top international pharmaceutical enterprise driven by scientific research and innovation.<\/p>\r\n\r\n
With more than 10,000 employees, the company's operating revenue in 2020 was RMB 33.683 billion, net profit attributable to owners of the parent company was RMB 2.820 billion, and the company's return on equity (ROE) has exceeded 20% for 14 consecutive years.<\/p>\r\n","url":"https:\/\/www.eastchinapharm.com\/","create_time":"2022-03-28 14:26:27"},{"id":49,"name":"TYK Medicines","logo":"https:\/\/www.panacro.com\/upload\/119c45b8a93dfe7f\/d9cad09fd39c329c.png","introduce":"
TYK Medicines, Inc. was established in 2018, positioned as an international innovative biotechnology company, and “In China, For Global”. The company focuses on the research and development of new anti-cancer drugs. Our mission is to gather global drug development expertise and “Together we search for the cure”.<\/p>\r\n","url":"http:\/\/www.tykmedicines.com\/","create_time":"2022-05-28 20:12:26"},{"id":50,"name":"Fudan-Zhangjiang","logo":"https:\/\/www.panacro.com\/upload\/453c3158c2fa93a5\/3deda9b767441ebc.png","introduce":"
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (“FDZJ”, “the Company”), established in November 1996, is located in Zhangjiang Hi-Tech park, Pudong, Shanghai. The shareholders of the Company are well-known companies such as Shanghai Pharmaceuticals Holding Co., Ltd.,<\/p>\r\n\r\n
Bearing the idea of “the more we explore, the healthier human beings will be” in mind, aiming at the establishment of an innovative bio-pharmaceutical company with the core capacity of the intellectual properties creation, the Company is principally engaged in research, development, manufacture and sale of innovative bio-pharmaceutical products. After years of the unremitting efforts, the Company has developed new technologies and products in the fields of genetic engineering drugs, photodynamic technology drugs, nano technology drugs and oral solid preparation technology drugs which created competitive advantages. It is planned to launch new drugs gradually in future.
\r\n <\/p>\r\n","url":"http:\/\/www.fd-zj.com\/DesktopModules\/HT\/chinese\/home\/Index.aspx","create_time":"2022-05-28 20:14:01"},{"id":51,"name":"CDBIO","logo":"https:\/\/www.panacro.com\/upload\/e2e3d555cacf6149\/3473d2f9ee3fc6ca.png","introduce":"
CDBIO is a high-tech enterprise established in June 2002 in Shenyang with the opportunity of introducing international advanced virus vaccine production technology platform from the United States. Adhering to the core values of "integrity, benevolence and harmony", the company is committed to research and development, production and promotion of "international level, domestic leading" biological products, the main products are Chengda Suda human rabies vaccine and Chengda Bao human Japanese encephalitis inactivated vaccine.<\/p>\r\n\r\n
Chengda Bio, with a registered capital of 360 million yuan and controlled by Liaoning Chengda Co., LTD. (600739), was listed on the National Equities Exchange and Exchange Board (NEEQ) on December 31, 2014. Its profitability and appreciation potential rank among neeQ enterprises. The production base is located in Hunnan National high-tech Park, shenyang, covering an area of nearly one hundred acres, building area of more than 50,000 square meters, more than 800 employees. It has 4 workshops of raw liquid, 3 preparation workshops and a pilot workshop. The annual production capacity of rabies vaccine for human use is 10 million doses, and je vaccine is 10 million doses. All workshops have successfully passed the national new GMP certification in 2010.<\/p>\r\n\r\n
Chengda Bio is a family vaccine manufacturer. Chengda Suda rabies vaccine has always taken the lead in the domestic market share, and has been exported to 32 countries including India, Pakistan, Thailand, the Philippines, Kenya, Ghana, Malawi and Georgia. Chengdalibao JE vaccine is currently the only inactivated JE vaccine in China. It has been successfully exported to Thailand and registered in Cambodia. The bivalent hemorrhagic fever with renal syndrome vaccine (Vero cell) independently developed based on the core technology platform has completed clinical research and is applying for production approval, aiming to be approved in 2020.<\/p>\r\n\r\n
On the one hand, Chengda Biotech accelerates the expansion of its product line and supplements conventional vaccine varieties from a high starting point; on the other hand, it actively promotes the research and development of multi-conjugate and multi-valent vaccines and innovative vaccines centering on the vaccine supply system of the National Expanded Program on Immunization. Chengda Bio always adheres to the values of "integrity and responsibility", establishes brand awareness and reputation in both domestic and international markets, and adheres to the product positioning of "international level, domestic leading", striving to become a trustworthy, respected and influential enterprise in the industry.<\/p>\r\n","url":"http:\/\/www.cdbio.cn\/","create_time":"2022-05-28 20:17:02"},{"id":52,"name":"Hefei Tianmai","logo":"https:\/\/www.panacro.com\/upload\/2c21018f3ed5e8b5\/e9ab42f77f553a5f.png","introduce":"
Hefei Tianmai Biotechnology Development Co., Ltd. is located in the national economic and technological development zone in Hefei, a well-known scientific and educational city in China, reputed as "a celebrated city with a big lake and a high ground of innovation". The company is an innovative high-tech bio-pharmaceutical enterprise committed to the introduction and absorption of international advanced biotechnology, and the development, production and sales of bio-pharmaceutical products.After nearly a decade of development, HTBT has invested 3.3 billion yuan in a variety of R&D and construction projects and plans to invest more than 5 billion yuan in the next decade.<\/p>\r\n","url":"http:\/\/www.htbt.com.cn\/","create_time":"2022-05-28 20:18:20"},{"id":53,"name":"Stemirna Therapeutics ","logo":"https:\/\/www.panacro.com\/upload\/d64d292a642a1da8\/bb84dcad18d5ccea.png","introduce":"
Stemirna Therapeutics is the first biotechnology company to bring mRNA therapeutics and high-end nanoparticle formulation platform to China. Through constant exploration and innovation, we strive to become a leading company in mRNA-based medicine in Asia, as well as in the world, so that we can provide more effective healthcare and therapeutic products.<\/p>\r\n\r\n
We believe that mRNA therapeutics is a promising field that could potentially revolutionize the way we treat cancer, infectious diseases, rare diseases and so on. Stemirna’s two major technology platforms are the foundation for our development of mRNA-based therapeutics and the key to our leading position in China.<\/p>\r\n\r\n
Stemirna Therapeutics was founded in the Zhangjiang Drug Valley of Shanghai, in 2016. Now it is located in the Jinqiao Pilot Free Trade Zone.<\/p>\r\n","url":"https:\/\/www.stemirna.com\/","create_time":"2022-05-28 20:20:59"},{"id":54,"name":"bebettermed","logo":"https:\/\/www.panacro.com\/upload\/0032eee6a6acb853\/2f039c3edbe1679f.png","introduce":"
BeBetter Med Inc. is a clinical-stage drug discovery and development company based in Guangzhou, China. BeBetter Med Inc. was founded in 2012 by overseas returnees, aimming to create advanced novel medicines to treat cancers, autoimmune diseases, metabolic diseases and other severe diseases. Through the years, we have developed strong expertise and outstanding facilities to perform comprehensive pharmaceutical research from compound design and synthesis to clinical development. The company expects to launch several new drugs over the next few years. <\/p>\r\n","url":"http:\/\/www.bebettermed.cn\/","create_time":"2022-05-28 20:25:27"},{"id":55,"name":"neptunus","logo":"https:\/\/www.panacro.com\/upload\/645efb583fba4853\/e65de1dd03b79b30.png","introduce":"
Neptunus bio was founded in 1992 and listed on the Shenzhen Stock Exchange in 1998. The company's business covers the whole industry chain of pharmaceutical commerce, pharmaceutical industry and pharmaceutical RESEARCH and development. In 2018, the operating revenue reached 38.381 billion yuan, with a year-on-year growth of 53.90%.<\/p>\r\n\r\n
As a drug service provider specializing in pharmaceutical commercial circulation in China, according to the national industrial policy and industry integration trend, the company plans its development layout scientifically, strengthens the development of upstream and downstream channels, and makes full use of the capital market to improve its own business development level, and realizes the steady improvement of scale and efficiency. At the same time, in the new version of GMP certification, drug bidding and procurement, drug costs and human resources costs rise, the company's pharmaceutical industry system companies adhere to the professional, standardized development ideas, steadily promote production and operation, the pharmaceutical industry system business maintained a stable growth.<\/p>\r\n\r\n
In 2016, the company carried out international cooperation to expand precision medical services. With the development of global science and technology, the emergence of new cancer treatment technology, cancer treatment has entered the era of precision medicine. Proton therapy as the choice of radiotherapy in the era of precision medicine, its excellent performance has been highly recognized by the global medical community. In order to achieve a leap-forward development in oncology and enhance its influence and competitiveness, The company is cooperating with Provision to introduce its proton therapy system into China.<\/p>\r\n","url":"https:\/\/www.neptunus.com\/","create_time":"2022-05-28 20:27:09"},{"id":56,"name":"Haisco Pharmaceutical","logo":"https:\/\/www.panacro.com\/upload\/6bcd4c9ff9b0f1c1\/7d44427afb98f320.png","introduce":"
Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Haisco” or the “Company”) was established in 2000. It is a diversified, professional pharmaceutical group listed company integrating R&D, manufacturing and sales of new drugs. The Company’s R&D strength ranks among the top in the chemical pharmaceutical industry, its market share in the parenteral nutrition segment is among the top, and it is the fifth largest manufacturer of drugs for liver disease in China, occupying an important position in the two subdivision markets of liver disease, digestion and anti-infection. There are more than 4,000 employees currently, including 50 PhDs and 360 Masters.<\/p>\r\n\r\n
The Company listed A-shares on the Shenzhen Stock Exchange on January 17, 2012, and achieved sales of RMB 3.330 billion and net profit of RMB 637 million in 2020.<\/p>\r\n\r\n
Haisco has strong technical strength, the R&D center has various scientific research personnel who are more than 700 in total, including numbers of PhDs and Masters. Currently, the R&D center has initiated 65 new projects in the specialized fields of innovative drugs and high-end generic drugs, involving multiple disease fields such as anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory diseases. Currently, there are a total of nine Category 1 new drugs under development. Ciprofol Injection, a Category 1 innovative drug, which is the first brand-new intravenous anesthetic drug developed by the Company independently with independent intellectual property rights in China, was successfully marketed during the reporting period. The first approved indication was sedation in gastrointestinal endoscopy, and the indication for induction of general anesthesia was also approved in February 2021, marking exciting results in the Company’s innovative drug research.<\/p>\r\n\r\n
The R&D Center owns the independent generic drug research building, the innovative drug research building and the intermediate experiment base, equipped with advanced and precise scientific research instruments, and the test conditions are at the leading level in China. Since its establishment in 2000, 66 varieties have been successfully developed, of which 21 have been marketed as the first generic drug, and the rate of marketed first generic drug exceeds 30%.<\/p>\r\n\r\n
The Company currently sells 46 varieties, most of which are the first or exclusive generic products in China, mainly including such as Polyene Phosphatidylcholine Injection, Fat-soluble Vitamin for Injection series, Dorasetron Mesylate Injection, Nalmefene Hydrochloride Injection, Flupentixol and Melitracen Tablets, Cefoperazone Sodium and Tazobactam Sodium for Injection, involving liver disease, parenteral nutrition, depression, and antibiotics fields, etc.<\/p>\r\n\r\n
Haisco has a sound sales network and mature marketing channels. According to the guidelines of “Self-building team, Collaborative operation”, the Company has built a huge sales network covering major provinces and cities in China. Guided by the policy of “Medical-driven, Academic-led and Sales-landing”, we adopt a diversified marketing model, innovate pilot projects, and promote work in all areas by drawing upon the experience gained on key points, transform to refinement, systematization, and platformization. At present, our Company has over 1,000 sales personnel and nearly 5,000 management representatives, covering more than 10,000 Grade II and above hospitals.<\/p>\r\n","url":"http:\/\/www.haisco.com\/","create_time":"2022-05-28 20:28:11"},{"id":57,"name":"Genhouse Bio","logo":"https:\/\/www.panacro.com\/upload\/14f8e28c00cd718f\/4fd4556d22305422.png","introduce":"
Genhouse Bio is a clinical-stage biotech company focusing on the development of global next-generation anti-cancer therapeutics<\/strong>, headquartered in the Suzhou Industry Park . The senior management team of Genhouse has multiple years of experience in new drug development, clinical research and corporate management. Genhouse has a clear focus on original innovation and overcoming those “undruggable” targets.<\/strong><\/p>\r\n\r\n Genhouse has established intergrated in-house drug development platforms. With these platforms, Genhouse has started to build a highly innovative anti-cancer pipeline <\/strong>and out-licensed the ex-China rights of its SHP2 inhibitor GH21 to HUYABIO , an international biotech company. Genhouse will continue to advance more innovative pipeline programs into global development.<\/p>\r\n","url":"https:\/\/www.genhousebio.com\/","create_time":"2022-05-28 20:29:10"},{"id":58,"name":"inkgopharma","logo":"https:\/\/www.panacro.com\/upload\/cf939114af227669\/56d9463988a59b1f.png","introduce":" Ginkgo Pharmaceutical (Suzhou) Co., Ltd. was founded in 2009, located in Suzhou Biomedical Industrial Park, is a biotechnology company with innovative drug research and development as its core business. The core team of the company has more than 10 years of experience in innovative drug research and development, and has formed a stable long-term cooperative relationship with a number of scientific research institutes. The company focuses on the treatment of viral diseases and aspires to become the leader of hepatitis treatment in China.<\/p>\r\n","url":"www.ginkgopharma.com","create_time":"2022-05-28 20:31:49"},{"id":59,"name":"Buchang Pharmaceuticals","logo":"https:\/\/www.panacro.com\/upload\/6451b11ccefdbb83\/33068e100c4cb2a1.png","introduce":" Buchang Pharmaceuticals is a China’s well-known enterprise which specializes in the R&D, production and sale of TCM patent medicines, supplemented by many fields, i.e., hi-tech industry and health industry. The Company has set up its production bases in Shandong, Shaanxi, Hebei and the Northeast China, with its marketing network spreading all over major provinces of China. Through years of development, the Company has owned a high-quality and professional team.<\/p>\r\n\r\n The Company was honored the titles of “Honest Taxpaying Enterprise”, “Assured Pharmaceutical Enterprise among People”, “China’s Top10 Best Pharmaceutical Enterprises”, etc. Danhong injection was awarded “Gold Medal for China’s first TCM Patent”; “Buchang Naoxintong” was honored the title of “Top 10 Best TCM Product Brands”. In 2013, Buchang received the honor as “2013 China Five-star Corporate Citizen”. In 2014, Buchang Pharmaceuticals won the “2014 Special Contribution Prize for the Chinese Philanthropy”. In 2015, Buchang Pharmaceuticals was honored the title of “Best Industrial Enterprise in Chinese Pharmaceutical R&D Production Lines of 2015”.<\/p>\r\n","url":"https:\/\/www.buchang.com\/","create_time":"2022-05-28 20:34:27"},{"id":60,"name":"BIOCAD","logo":"https:\/\/www.panacro.com\/upload\/31e83e55621fd1cc\/c2690724f62e0d06.png","introduce":" At BIOCAD, we aspire to deliver the next generation of medicines to patients with most serious health issues. To maximize the chances of success, the research is split across three diverse platforms specializing in different types of drug candidates: monoclonal antibodies, small molecules, and gene therapies. Within each of these platforms, all stages of development are carried out from target search and candidate selection to pilot clinical trials.<\/p>\r\n","url":"https:\/\/biocadglobal.com\/","create_time":"2022-05-28 20:36:57"},{"id":61,"name":"Guangzhou Xiangxue","logo":"https:\/\/www.panacro.com\/upload\/0cb9aac2a86bae4a\/a95447ec8f031d6a.png","introduce":" Guangzhou Xiangxue Pharmaceutical Co., Ltd ("XPH") is a pharmaceutical company foucs on Traditional Chinese Medicine ("TCM") development and modernization as well a utilizing cutting edge biotechnology to treat cancer in the modern age. <\/p>\r\n\r\n Founded in 1997, XPH has been listed as a public company on the Shenzhen Stock Exchange (Stock Code: 300147) since 2010, and currently has a Market Value of More than 9.7 Billion RMB.<\/p>\r\n","url":"https:\/\/www.xphcn.com\/","create_time":"2022-05-28 20:38:14"},{"id":62,"name":"Lepu Biopharma","logo":"https:\/\/www.panacro.com\/upload\/fccdbe6f6fe1c64d\/fa2a649a2e24cffe.png","introduce":" Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics with a strong China root and global vision. We have developed a strong oncology-focused pipeline of drug candidates, including ADCs, oncolytic virus drugs and immunotherapies at clinical and pre-clinical stages. We plan to commercialize our pipeline products in China through dedicated sales and marketing forces and in overseas markets, such as the U.S. and European markets, via partnerships.<\/p>\r\n","url":"https:\/\/www.lepubiopharma.com\/","create_time":"2022-05-28 20:40:59"},{"id":63,"name":"Lilly","logo":"https:\/\/www.panacro.com\/upload\/bfff3727d86ab813\/aca037f3aebe1b07.png","introduce":" Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better." <\/p>\r\n\r\n More than 145 years later, we remain committed to his vision through every aspect of our business and the people we serve starting with those who take our medicines, and extending to health care professionals, employees and the communities in which we live. <\/p>\r\n","url":"https:\/\/www.lilly.com.cn\/index.html#\/","create_time":"2022-05-28 20:43:26"}]}